• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓间充质干细胞来源的外泌体 microRNA-193a 通过靶向 LRRC1 降低非小细胞肺癌细胞对顺铂的耐药性。

Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1.

机构信息

Department of Internal Medicine, The Affiliated Tumor Hospital of Zhengzhou University, He'nan Cancer Hospital, Zhengzhou, He'nan Province, 450008, China.

Department of Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, 610064, China.

出版信息

Cell Death Dis. 2020 Sep 25;11(9):801. doi: 10.1038/s41419-020-02962-4.

DOI:10.1038/s41419-020-02962-4
PMID:32978367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7519084/
Abstract

Exosomes are small endogenous membrane vesicles that can mediate cell communication by transferring genetic materials. Based on that, exosomes have always been discussed as a cargo carrier for microRNA (miRNA) transportation. Accumulating data have reported the inhibitory effects of microRNA-193a (miR-193a) on non-small cell lung cancer (NSCLC) cell progression. However, the mechanisms of miR-193a delivery to cancer cells and miR-193a in exosomes have not been explored clearly in NSCLC. Given that, this work aims to decode exosomal miR-193a in cisplatin (DDP) resistance of NSCLC cells. A549 and H1299 cell lines were screened out and their parent cells and drug-resistant cells were co-cultured with human bone marrow mesenchymal stem cells (BMSCs)-derived exosomes (BMSC-Exo) that had been transfected with miR-193a mimic or si-LRRC1 to detect the colony formation, migration, apoptosis, invasion and proliferation of NSCLC cells. In vivo experiment was conducted to verify the in vitro results. BMSC-Exo with upregulated miR-193a and downregulated LRRC1 suppressed colony formation, invasion, proliferation and migration as well as advanced apoptosis of NSCLC parent cells and drug-resistant cells. BMSC-Exo combined with upregulated miR-193a reduced tumor volume and weight in mice with NSCLC. Functional studies report that BMSC-Exo shuffle miR-193a to suppress the colony formation, invasion, migration, and proliferation as well as advance apoptosis of NSCLC DDP-resistant cells via downregulating LRRC1.

摘要

外泌体是一种小的内源性膜囊泡,可以通过转移遗传物质来介导细胞间通讯。基于此,外泌体一直被认为是 microRNA (miRNA) 运输的载体。越来越多的数据报道了 microRNA-193a (miR-193a) 对非小细胞肺癌 (NSCLC) 细胞进展的抑制作用。然而,miR-193a 递送到癌细胞的机制以及 NSCLC 中外泌体中的 miR-193a 尚未得到明确的研究。有鉴于此,本工作旨在解码 NSCLC 细胞顺铂 (DDP) 耐药中外泌体 miR-193a。筛选出 A549 和 H1299 细胞系,并将其亲本细胞和耐药细胞与转染 miR-193a 模拟物或 si-LRRC1 的人骨髓间充质干细胞 (BMSC) 衍生的外泌体 (BMSC-Exo) 共培养,以检测 NSCLC 细胞的集落形成、迁移、凋亡、侵袭和增殖。进行体内实验以验证体外结果。上调 miR-193a 并下调 LRRC1 的 BMSC-Exo 抑制 NSCLC 亲本细胞和耐药细胞的集落形成、侵袭、增殖和迁移,并促进其凋亡。BMSC-Exo 联合上调 miR-193a 可减少荷 NSCLC 小鼠的肿瘤体积和重量。功能研究表明,BMSC-Exo 通过下调 LRRC1 将 miR-193a 转移到 NSCLC DDP 耐药细胞中,抑制其集落形成、侵袭、迁移、增殖并促进其凋亡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/937f44c0ca3f/41419_2020_2962_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/52591239a55b/41419_2020_2962_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/cb14bf5732b3/41419_2020_2962_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/30c7609613ae/41419_2020_2962_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/bcc5153ba082/41419_2020_2962_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/a890bac7ad2b/41419_2020_2962_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/35ddd40df4a1/41419_2020_2962_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/937f44c0ca3f/41419_2020_2962_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/52591239a55b/41419_2020_2962_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/cb14bf5732b3/41419_2020_2962_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/30c7609613ae/41419_2020_2962_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/bcc5153ba082/41419_2020_2962_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/a890bac7ad2b/41419_2020_2962_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/35ddd40df4a1/41419_2020_2962_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d7/7519084/937f44c0ca3f/41419_2020_2962_Fig7_HTML.jpg

相似文献

1
Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1.骨髓间充质干细胞来源的外泌体 microRNA-193a 通过靶向 LRRC1 降低非小细胞肺癌细胞对顺铂的耐药性。
Cell Death Dis. 2020 Sep 25;11(9):801. doi: 10.1038/s41419-020-02962-4.
2
BMSCs-Derived Exosomal MiR-126-3p Inhibits the Viability of NSCLC Cells by Targeting PTPN9.骨髓间充质干细胞来源的外泌体 miR-126-3p 通过靶向 PTPN9 抑制非小细胞肺癌细胞的活力。
J BUON. 2021 Sep-Oct;26(5):1832-1841.
3
Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT.低氧骨髓间充质干细胞衍生的外泌体 miRNAs 通过 STAT3 诱导的 EMT 促进肺癌细胞转移。
Mol Cancer. 2019 Mar 13;18(1):40. doi: 10.1186/s12943-019-0959-5.
4
Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.外泌体传递的 circVMP1 通过靶向 miR-524-5p-METTL3/SOX2 轴促进非小细胞肺癌的进展和顺铂耐药性。
Drug Deliv. 2022 Dec;29(1):1257-1271. doi: 10.1080/10717544.2022.2057617.
5
Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.外泌体 circ_PIP5K1A 通过 miR-101/ABCC1 轴调控非小细胞肺癌的进展和顺铂敏感性。
Mol Cell Biochem. 2021 Jun;476(6):2253-2267. doi: 10.1007/s11010-021-04083-8. Epub 2021 Feb 11.
6
Exosomal microRNA-144 from bone marrow-derived mesenchymal stem cells inhibits the progression of non-small cell lung cancer by targeting CCNE1 and CCNE2.骨髓间充质干细胞来源的外泌体 microRNA-144 通过靶向 CCNE1 和 CCNE2 抑制非小细胞肺癌的进展。
Stem Cell Res Ther. 2020 Feb 26;11(1):87. doi: 10.1186/s13287-020-1580-7.
7
Bone marrow mesenchymal stem cells-derived exosomal miR-145-5p reduced non-small cell lung cancer cell progression by targeting SOX9.骨髓间充质干细胞衍生的外泌体 miR-145-5p 通过靶向 SOX9 减少非小细胞肺癌细胞的进展。
BMC Cancer. 2024 Jul 22;24(1):883. doi: 10.1186/s12885-024-12523-z.
8
Cancer-associated fibroblasts secreted miR-103a-3p suppresses apoptosis and promotes cisplatin resistance in non-small cell lung cancer.癌相关成纤维细胞分泌的 miR-103a-3p 抑制非小细胞肺癌细胞凋亡并促进顺铂耐药。
Aging (Albany NY). 2021 May 17;13(10):14456-14468. doi: 10.18632/aging.103556.
9
MicroRNA-631 deriving from bone marrow mesenchymal stem cell exosomes facilitates the malignant behavior of non-small cell lung cancer via modulating the E2F family of transcription factor 2/phosphatidylinositol 3-kinase/Akt signaling pathway.微小 RNA-631 来源于骨髓间充质干细胞外泌体,通过调节 E2F 转录因子家族 2/磷脂酰肌醇 3-激酶/ Akt 信号通路促进非小细胞肺癌的恶性行为。
Bioengineered. 2022 Apr;13(4):8382-8395. doi: 10.1080/21655979.2022.2036891.
10
Inhibitory role of bone marrow mesenchymal stem cells-derived exosome in non-small-cell lung cancer: microRNA-30b-5p, EZH2 and PI3K/AKT pathway.骨髓间充质干细胞来源的外泌体在非小细胞肺癌中的抑制作用:miRNA-30b-5p、EZH2 和 PI3K/AKT 通路。
J Cell Mol Med. 2023 Nov;27(22):3526-3538. doi: 10.1111/jcmm.17933. Epub 2023 Sep 12.

引用本文的文献

1
Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms.表观遗传机制对肺癌顺铂耐药性的调控
Clin Epigenetics. 2025 Aug 24;17(1):145. doi: 10.1186/s13148-025-01961-6.
2
Mesenchymal stem cell-derived lncRNAs NKILA contributes to stemness and chemoresistance by fatty acid oxidation in gastric cancer miR-485-5p/STAT3.间充质干细胞来源的长链非编码RNA NKILA通过脂肪酸氧化在胃癌miR-485-5p/STAT3中促进干性和化疗耐药性。
World J Gastrointest Oncol. 2025 Aug 15;17(8):105006. doi: 10.4251/wjgo.v17.i8.105006.
3
Mesenchymal stem cells promote erlotinib resistance in non-small cell lung cancer through the HGF-AKT/ERK1/2-OPN pathway.

本文引用的文献

1
The p53/miR-193a/EGFR feedback loop function as a driving force for non-small cell lung carcinoma tumorigenesis.p53/miR-193a/EGFR反馈环作为非小细胞肺癌肿瘤发生的驱动力发挥作用。
Ther Adv Med Oncol. 2019 May 23;11:1758835919850665. doi: 10.1177/1758835919850665. eCollection 2019.
2
Urinary Exosomal miR-193a Can Be a Potential Biomarker for the Diagnosis of Primary Focal Segmental Glomerulosclerosis in Children.尿外泌体miR-193a可作为儿童原发性局灶节段性肾小球硬化症诊断的潜在生物标志物。
Biomed Res Int. 2017;2017:7298160. doi: 10.1155/2017/7298160. Epub 2017 Jan 29.
3
Cloning and characterization of a novel splice variant of the brain-specific protein densin-180.
间充质干细胞通过HGF-AKT/ERK1/2-OPN途径促进非小细胞肺癌对厄洛替尼的耐药性。
Am J Transl Res. 2025 Jul 15;17(7):4952-4963. doi: 10.62347/RKYL8675. eCollection 2025.
4
Unveiling the power of exosomal non-coding RNAs: key drivers of lung cancer progression in the tumor microenvironment.揭示外泌体非编码RNA的力量:肿瘤微环境中肺癌进展的关键驱动因素
Med Oncol. 2025 Jul 1;42(8):308. doi: 10.1007/s12032-025-02791-5.
5
Exosome, an important transmitter in the drug resistance of non-small cell lung cancer.外泌体,非小细胞肺癌耐药性中的一种重要传递者。
Front Oncol. 2025 May 15;15:1539047. doi: 10.3389/fonc.2025.1539047. eCollection 2025.
6
Methylation-Mediated Silencing of miR-124-3 Regulates LRRC1 Expression and Promotes Oral Cancer Progression.miR-124-3的甲基化介导沉默调控LRRC1表达并促进口腔癌进展。
Cancers (Basel). 2025 Mar 28;17(7):1136. doi: 10.3390/cancers17071136.
7
Revolutionizing lung cancer treatment: harnessing exosomes as early diagnostic biomarkers, therapeutics and nano-delivery platforms.革新肺癌治疗:利用外泌体作为早期诊断生物标志物、治疗剂和纳米递送平台。
J Nanobiotechnology. 2025 Mar 21;23(1):232. doi: 10.1186/s12951-025-03306-0.
8
Intratumoral heterogeneity and drug resistance in cancer.肿瘤内异质性与癌症耐药性
Cancer Cell Int. 2025 Mar 18;25(1):103. doi: 10.1186/s12935-025-03734-w.
9
Extracellular Vesicles as Mediators and Potential Targets in Combating Cancer Drug Resistance.细胞外囊泡作为对抗癌症耐药性的介质和潜在靶点。
Molecules. 2025 Jan 23;30(3):498. doi: 10.3390/molecules30030498.
10
Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment.癌症治疗中基于细胞外囊泡的药物递送系统克服耐药性
Cancer Drug Resist. 2024 Dec 12;7:50. doi: 10.20517/cdr.2024.107. eCollection 2024.
脑特异性蛋白致密素-180新型剪接变体的克隆与鉴定
Int J Mol Med. 2003 Feb;11(2):257-60.